FRE04

FRE04 appears to be an internal Freya Biosciences program code associated with the company's bacterial vaginosis effort, but the exact active substance, composition, modality, mechanism, dosage form, and route of administration could not be verified from publicly accessible primary sources. Freya Biosciences publicly describes a women’s health pipeline focused on microbial or immunology-based therapies for conditions including bacterial vaginosis and preterm birth risk, but its currently named public pipeline assets are FB301 and FB401 rather than FRE04. Based on the available evidence, FRE04 is best treated as an unconfirmed sponsor code for a specific investigational candidate in bacterial vaginosis, with insufficient public detail to assign a precise mechanism of action or product identity.